Evofem Bioscienc Financials
Evofem Bioscienc (EVFM) reported $18.0M in revenue over the twelve months to Jun 30, 2026, up 4.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A cost-reset turnaround pushed accounting profit positive, but cash conversion still trails the income statement.
FY2025 operating profit arrived while operating cash flow was still-$2.0M , so earnings and cash are not yet moving together. That gap matches receivables swelling to$12.5M , meaning a large share of reported sales is still sitting in customer balances instead of funding the business.
The improvement since FY2022 looks more like a cost reset than a volume story: revenue only moved from
Capital intensity is low because free cash flow stayed close to operating cash flow and capital spending was only
Financial Health Signals
Evofem Bioscienc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Evofem Bioscienc scores -64.53, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.0M) relative to total liabilities ($94.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Evofem Bioscienc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Evofem Bioscienc used $5.09 of operating cash (-$2.0M OCF vs $391K net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Evofem Bioscienc earns $1.43 in operating income for every $1 of interest expense ($3.4M vs $2.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Evofem Bioscienc generated $20.2M in revenue in fiscal year 2025. This represents an increase of 4.2% from the prior year.
Evofem Bioscienc's EBITDA was $3.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 155.4% from the prior year.
Evofem Bioscienc reported $391K in net income in fiscal year 2025. This represents an increase of 104.4% from the prior year.
Evofem Bioscienc earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Cash & Balance Sheet
Evofem Bioscienc recorded an outflow of $2.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 48.8% from the prior year.
Evofem Bioscienc held $578K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Evofem Bioscienc's gross margin was 77.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.1 percentage points from the prior year.
Evofem Bioscienc's operating margin was 16.7% in fiscal year 2025, reflecting core business profitability. This is up 56.4 percentage points from the prior year.
Evofem Bioscienc's net profit margin was 1.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 47.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Evofem Bioscienc invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
EVFM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M+192.9% | $899K-90.6% | $9.6M+93.1% | $5.0M+2.6% | $4.8M+471.0% | $845K-88.1% | $7.1M+58.0% | $4.5M |
| Cost of Revenue | $511K+24.6% | $410K-84.2% | $2.6M+186.4% | $905K+19.9% | $755K+106.8% | $365K-75.9% | $1.5M+74.0% | $869K |
| Gross Profit | $2.1M+333.9% | $489K-93.0% | $7.0M+72.2% | $4.0M-0.6% | $4.1M+747.9% | $480K-91.4% | $5.6M+54.2% | $3.6M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | $649K+95.5% | $332K |
| SG&A Expenses | $1.8M-22.9% | $2.4M+116.2% | $1.1M-47.5% | $2.1M+13.3% | $1.8M-22.1% | $2.4M-30.9% | $3.4M+12.1% | $3.1M |
| Operating Income | -$2.5M+45.5% | -$4.6M-236.6% | $3.3M+251.7% | $951K+176.0% | -$1.3M-482.6% | $327K+132.6% | -$1.0M+58.9% | -$2.4M |
| Interest Expense | N/A | $614K+2.0% | $602K+0.5% | $599K+1.9% | $588K+1.9% | $577K0.0% | $577K+3.8% | $556K |
| Income Tax | N/A | -$1K | N/A | -$4K-157.1% | $7K | N/A | N/A | -$8K |
| Net Income | -$11.0M-101.9% | -$5.5M-296.0% | $2.8M+277.7% | -$1.6M+12.1% | -$1.8M-286.6% | $956K+131.5% | -$3.0M-28.4% | -$2.4M |
| EPS (Diluted) | -$0.08-100.0% | -$0.04-300.0% | $0.02+300.0% | -$0.010.0% | -$0.01 | $0.00+100.0% | -$0.020.0% | -$0.02 |
EVFM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.5M+1.1% | $7.4M-63.3% | $20.3M+46.8% | $13.8M-4.0% | $14.4M+11.7% | $12.9M-45.9% | $23.8M-0.6% | $23.9M |
| Current Assets | $6.1M+0.4% | $6.1M-60.4% | $15.3M+93.0% | $7.9M-11.7% | $9.0M+52.7% | $5.9M-56.8% | $13.6M+58.7% | $8.6M |
| Cash & Equivalents | $285K-80.9% | $1.5M+158.0% | $578K-31.2% | $840K+12.3% | $748K+238.5% | $221K-70.2% | $741K+2.6% | $722K |
| Inventory | $2.2M+14.0% | $1.9M+67.4% | $1.1M-33.0% | $1.7M-11.6% | $1.9M-15.8% | $2.3M+43.5% | $1.6M+7.8% | $1.5M |
| Accounts Receivable | $2.5M+345.9% | $560K-95.5% | $12.5M+181.4% | $4.4M-10.1% | $4.9M+329.4% | $1.1M-88.3% | $9.8M+82.3% | $5.4M |
| Total Liabilities | $95.0M+11.7% | $85.1M-10.1% | $94.6M+6.5% | $88.9M+5.8% | $84.0M+1.9% | $82.5M-13.2% | $95.0M+5.5% | $90.1M |
| Current Liabilities | $88.6M+12.5% | $78.8M-7.2% | $84.8M+8.5% | $78.2M+5.8% | $73.9M+4.3% | $70.9M-11.9% | $80.4M+5.5% | $76.3M |
| Total Equity | -$87.5M-12.7% | -$77.6M-4.4% | -$74.3M+1.0% | -$75.1M-7.8% | -$69.6M0.0% | -$69.6M+2.3% | -$71.3M-0.5% | -$70.9M |
| Retained Earnings | -$914.0M-1.2% | -$902.9M-0.6% | -$897.4M+0.3% | -$900.2M-0.2% | -$898.5M-0.2% | -$896.7M+0.1% | -$897.7M-0.3% | -$894.6M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
EVFM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M-236.5% | $2.3M+7322.6% | $31K-90.8% | $336K+111.5% | -$2.9M-621.3% | $560K+123.3% | -$2.4M-424.6% | -$459K |
| Capital Expenditures | $0-100.0% | $2K-33.3% | $3K | $0 | N/A | N/A | $0 | $0 |
| Free Cash Flow | -$3.1M-236.6% | $2.3M+8110.7% | $28K-91.7% | $336K | N/A | N/A | -$2.4M-424.6% | -$459K |
| Investing Cash Flow | $0+100.0% | -$2K+33.3% | -$3K | $0+100.0% | -$2K+96.5% | -$57K-23.9% | -$46K+91.0% | -$509K |
| Financing Cash Flow | $1.0M+310.0% | -$498K-71.7% | -$290K-18.9% | -$244K-109.5% | $2.6M+1996.3% | -$135K-105.5% | $2.5M+147.8% | $998K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EVFM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.6%+26.2pp | 54.4%-18.5pp | 72.9%-8.8pp | 81.7%-2.6pp | 84.4%+27.6pp | 56.8%-21.9pp | 78.7%-1.9pp | 80.7% |
| Operating Margin | -94.5% | -508.2% | 35.0%+15.8pp | 19.2%+45.1pp | -25.9%-64.6pp | 38.7%+52.8pp | -14.1%+40.1pp | -54.3% |
| Net Margin | -419.1% | -607.9% | 29.2%+60.8pp | -31.7%+5.3pp | -37.0% | 113.1% | -42.8%+9.9pp | -52.6% |
| Return on Assets | -146.7%-73.3pp | -73.4%-87.2pp | 13.8%+25.1pp | -11.4%+1.0pp | -12.4%-19.8pp | 7.4%+20.2pp | -12.8%-2.9pp | -9.9% |
| Current Ratio | 0.070.0x | 0.08-0.1x | 0.18+0.1x | 0.100.0x | 0.120.0x | 0.08-0.1x | 0.17+0.1x | 0.11 |
| FCF Margin | -119.3% | 255.7% | 0.3%-6.5pp | 6.8% | N/A | N/A | -33.9%-23.7pp | -10.2% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$74.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Evofem Bioscienc Ranks
Frequently Asked Questions
What is Evofem Bioscienc's annual revenue?
Evofem Bioscienc (EVFM) reported $20.2M in total revenue for fiscal year 2025. This represents a 4.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Evofem Bioscienc's revenue growing?
Evofem Bioscienc (EVFM) revenue grew by 4.2% year-over-year, from $19.4M to $20.2M in fiscal year 2025.
Is Evofem Bioscienc profitable?
Yes, Evofem Bioscienc (EVFM) reported a net income of $391K in fiscal year 2025, with a net profit margin of 1.9%.
What is Evofem Bioscienc's EBITDA?
Evofem Bioscienc (EVFM) had EBITDA of $3.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Evofem Bioscienc's gross margin?
Evofem Bioscienc (EVFM) had a gross margin of 77.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Evofem Bioscienc's operating margin?
Evofem Bioscienc (EVFM) had an operating margin of 16.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Evofem Bioscienc's net profit margin?
Evofem Bioscienc (EVFM) had a net profit margin of 1.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Evofem Bioscienc's free cash flow?
Evofem Bioscienc (EVFM) recorded an outflow of $2.0M in free cash flow during fiscal year 2025. This represents a 48.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Evofem Bioscienc's operating cash flow?
Evofem Bioscienc (EVFM) recorded an outflow of $2.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Evofem Bioscienc's total assets?
Evofem Bioscienc (EVFM) had $20.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Evofem Bioscienc's capital expenditures?
Evofem Bioscienc (EVFM) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Evofem Bioscienc's current ratio?
Evofem Bioscienc (EVFM) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Evofem Bioscienc's return on assets (ROA)?
Evofem Bioscienc (EVFM) had a return on assets of 1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Evofem Bioscienc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Evofem Bioscienc (EVFM) held $578K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Evofem Bioscienc's debt-to-equity ratio negative or not reported?
Evofem Bioscienc (EVFM) has negative shareholder equity of -$74.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Evofem Bioscienc's Altman Z-Score?
Evofem Bioscienc (EVFM) has an Altman Z-Score of -64.53, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Evofem Bioscienc's Piotroski F-Score?
Evofem Bioscienc (EVFM) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Evofem Bioscienc's earnings high quality?
For every $1 of reported earnings, Evofem Bioscienc (EVFM) used $5.09 of operating cash (-$2.0M OCF vs $391K net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Evofem Bioscienc cover its interest payments?
Evofem Bioscienc (EVFM) has an interest coverage ratio of 1.43x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.